Data on the natural history, clinical endpoints, and clinical relevance of biomarkers are limited in these selected type 1 interferonopathies (AGS, SAVI, FCL, and COPA syndrome), and will be of utmost importance to support the development of novel therapies for these diseases. This non-IMP clinical trial is planned to fill that gap.
